Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

17.33USD
26 Apr 2018
Change (% chg)

$0.32 (+1.88%)
Prev Close
$17.01
Open
$17.09
Day's High
$17.65
Day's Low
$17.00
Volume
294,496
Avg. Vol
499,057
52-wk High
$23.50
52-wk Low
$5.47

Select another date:

Tue, Mar 27 2018

BRIEF-Shrotriya May Sell Up To 1 Mln Shares Of Spectrum Pharmaceuticals' Common Stock

* RAJESH C. SHROTRIYA - SHROTRIYA MAY SELL UP TO 1 MILLION SHARES OF SPECTRUM PHARMACEUTICALS' COMMON STOCK BETWEEN MARCH 26 AND JUNE 29 - SEC FILING‍​ Source text: (https://bit.ly/2pKokJc) Further company coverage:

BRIEF-Spectrum Pharma Q4 Loss Per Share $0.29

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its Board

* SPECTRUM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM L. ASHTON TO ITS BOARD OF DIRECTORS

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

Select another date: